Recognizing the need to incorporate biologic factors (tumor grade, proliferation rate, and ER/PR/HER2 expression) and gene expression-based prognostic panels, in addition to the traditional anatomic factors into its staging system, the AJCC recently extensively revised its eighth edition of the TNM classification system, which remains the worldwide basis for BC staging. This evidence concerns the gene ESR1 and breast cancer.